Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Porin A (PorA) is a major class 1 outer membrane protein of Neisseria meningitidis, functioning as a selective cation-permeable channel essential for nutrient uptake and metabolic waste export (UniProt P0A105). The P1.4 variant refers to a specific serosubtype of the PorA protein, notably prevalent in epidemic strains such as the NZ98/254 strain responsible for the New Zealand meningococcal outbreak. Outer membrane vesicles (OMVs) are proteoliposomes naturally shed by the bacteria that contain PorA along with other critical antigens like PorB, Opa, and Opc, which play roles in adhesion and immune evasion (Holst et al., 2009, Vaccine). In therapeutic contexts, these OMVs are utilized as vaccine components to elicit a robust immune response. The primary mechanism of action involves the generation of bactericidal antibodies that target the variable regions of PorA, leading to complement-mediated lysis of the pathogen (Bambini et al., 2013, Vaccine). Because PorA is highly antigenically variable, OMV-based vaccines are often tailored to specific regional strains or combined with other recombinant proteins to broaden protection against serogroup B meningococci.
Induction of serum bactericidal antibodies (SBA) that facilitate complement-mediated killing of Neisseria meningitidis through recognition of PorA and other OMV-associated surface antigens (O'Hallahan et al., 2004, Lancet Infectious Diseases).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Porin A (PorA) P1.4 and associated outer membrane vesicle antigens of Neisseria meningitidis group B (PorA P1.4 OMV).